Increased CR rates vs BR at end of treatment (EOT) (40% vs 18%, respectively) 1*

Objective response rate at EOT*:
45% (95% CI: 29, 62; n=18/40) with POLIVY+BR vs 18% (95% CI: 7, 33; n=7/40) with BR

PET-CT–based response per modified Lugano 2014 criteria. Bone marrow confirmation of PET-CT CR was required. PET-CT PR required meeting both PET criteria and CT criteria for PR.
*EOT was defined as 6 to 8 weeks after Day 1 of cycle 6 or last study treatment.
PET=positron emission tomography.

Polatuzumab vedotin-piiq (POLIVY) + bendamustine + rituximab (BR) is included in the NCCN Guidelines® as a preferred treatment option (Category 2A) based on the randomized, controlled GO29365 trial 1,2 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend polatuzumab vedotin-piiq (POLIVY) + bendamustine + rituximab (BR) as a preferred treatment option, after at least 2 prior therapies, for patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for transplant (Category 2A). 2

The National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 27, 2020. To view the most recent and complete version of the guideline, go to NCCN.org.